bsm-54138R-BF680 [Conjugated Primary Antibody]
JAK1 Recombinant Antibody, AbBy Fluor-680 Conjugated
www.biossusa.com
support@biossusa.com
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: JAK1

Clonality: Recombinant

Isotype: IgG

Entrez Gene: 3716

Swiss Prot: P23458

Source: Recombinant protein corresponding to human JAK1 aa 900-1154

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

JAK1 (Janus kinase 1) belongs to the family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK1. JAK1 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to cis elements upstream of target gene promoters to regulate transcription. Upon ligand binding, JAK1 undergoes tyrosine phosphorylation and catalytic activation in an interdependent manner. Phosphorylation of tyrosine residues at position 1022 and 1023 is believed to function in the activation of catalytic events. The canonical JAK-Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival, and host resistance to pathogens. Altering JAK-Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies.

Conjugation: AbBy Fluor-680

Excitation/ Emission: 679nm/702nm

Size: 100µL

Concentration: Lot dependent

Applications: WB(WB(1:500-1000))
FCM(FCM(1:50-100))
IF(IHC-P)(IF(IHC-P)(1:100-500))

Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Hui Yan. et al. Elaboration a ROS-responsive darutigenol prodrug nanoassemblies for inflammatory arthritis treatment. NANO TODAY. 2024 Apr;55:10222Read more>>
VALIDATION IMAGES